IFNG and Hand-foot syndrome: In preclinical studies, ruxolitinib was found to downregulate MHC class II expression in cultured murine hair bulbs and around HFs after IFN-γ exposure and to stimulate anagen reentry–related molecules in cultured human dermal papilla cells via the Wnt/β-catenin pathway (165).